<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119233</url>
  </required_header>
  <id_info>
    <org_study_id>STP 203</org_study_id>
    <nct_id>NCT03119233</nct_id>
  </id_info>
  <brief_title>The DETOUR2 Clinical Study</brief_title>
  <official_title>The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PQ Bypass, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PQ Bypass, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-arm, multi-center, international clinical investigation to evaluate the
      safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant
      stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DETOUR2 study is a prospective, single-arm, multi-center, international, non-randomized,
      safety and effectiveness clinical investigation of the PQ Bypass system.

      The PQ Bypass System is intended to improve blood flow in patients with symptomatic
      peripheral arterial disease due to symptomatic femoropopliteal chronic total occlusions ≥ 20
      cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or
      Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic
      total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis
      (complex TASC C), with reference vessel diameters ranging from 5.0 - 6.7 mm, by investigator
      visual assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The absence of clinically-driven target lesion revascularization and/or absence of recurrent target lesion diameter stenosis &gt;50% by imaging (e.g., duplex ultrasound (peak systolic velocity ratio of &gt;2.5) or invasive angiography) with the stent or immediately 1 cm above or below the treated segment.). When both modalities are available, angiography takes precedence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of(above the Treated Limb,ankle), Symptomatic Deep Vein Thrombosis (DVT), Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PQ Bypass System</intervention_name>
    <description>Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).</description>
    <arm_group_label>Single-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects are required to meet the following inclusion criteria in order to be
        considered eligible for participation in the study:

        General Inclusion Criteria

          1. Age &gt; 18 and ≤ 90 years of age.

          2. Willing and able to provide informed consent.

          3. Subject is willing to undergo all follow-up assessments according to the specified
             schedule over 36 months.

             Clinical Inclusion Criteria

          4. Chronic, symptomatic lower limb ischemia defined as Rutherford clinical categories 3,
             4, or 5.

          5. Venous Clinical Severity Score &lt; 3.

          6. Subject is a suitable candidate for angiography and endovascular intervention and, if
             required, is eligible for standard surgical repair.

             Angiographic Inclusion Criteria

          7. Symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include
             de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal
             lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a
             ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C),
             by investigator visual assessment.

          8. Reference vessel diameter ≥ 4.5 and ≤ 6.7 mm, by investigator visual assessment.

          9. Subject has a patent popliteal artery (&lt;50% stenosis) distal to the landing zone

         10. Able to successfully access the SFA origin for entry of the crossing device.

         11. At least one patent infrapopliteal vessel (&lt;50% stenosis) with run-off to the ankle or
             foot.

         12. A significant stenosis (≥ 50%) or occlusion of an ipsilateral, inflow artery (e.g.
             aortoiliac, common femoral) must be successfully treated (use of investigational
             treatment prohibited) prior to treatment of the target lesion. Successful treatment is
             defined as no complications and less than 30% residual stenosis following
             intervention.

        General Exclusion Criteria

          1. Participating in another investigational clinical study.

          2. Anticipated life expectancy less than 1 year or medical comorbid condition(s) that
             could limit the subject's ability to comply with the requirements of the trial.

          3. Subject has other medical, social or psychological problems that, in the opinion of
             the investigator, preclude them from receiving this treatment, and the procedures and
             evaluations pre- and post-treatment.

             Clinical Exclusion Criteria

          4. History of deep vein thrombosis on either limb.

          5. Thrombophlebitis, within the previous 30 days.

          6. 6. Planned major amputation of the target limb, including minor amputation (above the
             ankle).

          7. Prior distal amputation (above the transmetatarsal) of the target limb.

          8. Known or suspected active infection at the time of the procedure (e.g., WIfI foot
             infection grade 3: Severe infection. Local infection with systemic inflammatory
             response syndrome [SIRS])

          9. Rutherford clinical category 0, 1, 2 or 6.

         10. Has acute or chronic renal disease with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated
             serum creatinine &gt;2.5mg/dL (220µmol/L) or on dialysis.

         11. Known hypersensitivity/allergy to the investigational devices and/or required
             pharmacotherapy that cannot be safely managed.

         12. Morbid obesity that does not allow for safe vascular access or imaging.

         13. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with
             platelet count less than 100,000/microliter or INR &gt; 1.8.

         14. Requires coronary or peripheral procedure within 30 days prior to or planned within 30
             days post treatment of the target lesion.

         15. Has a known history of intracranial bleeding or aneurysm, myocardial infarction or
             stroke within the last 3 months.

         16. Subject is pregnant or breast-feeding. Angiographic Exclusion Criteria

         17. Stent within 3 cm of SFA ostium.

         18. Previous bypass surgery on the target limb.

         19. Subject has significant disease or obstruction (≥50%) of the inflow tract that has not
             been successfully treated at the time of the index procedure (success measured as ≤30%
             residual stenosis, without complication)

         20. Presence of aneurysm or acute thrombus in the target limb.

         21. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where
             complete resolution of the thrombus was not achieved.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Cardiac and Vascular Amputation Prevention Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Lyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Versprille</last_name>
    <phone>+1 (908) 328-5787</phone>
    <email>vversprille@pqbypass.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Bernard's Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barry Tedder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vasili Lendel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiovascular Specialists</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ajanta De, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain VA Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMITA Health Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrei Pop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matt Eagleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiac and Vascular Amputation Prevention Centers</name>
      <address>
        <city>Grandville</city>
        <state>Michigan</state>
        <zip>49418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jihad Mustapha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiac &amp; Vascular Research Center of Nothern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Ricci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steve Henao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian / Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Schutzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital - The Carl &amp; Edyth Lindner Center for Research &amp; Education</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Corl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinical Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean Lyden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Soukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Gray, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Mewissen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Hochsauerland GmbH</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dierk Scheinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dainis Krievins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gdańsk Medical University</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grzegorz Halena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

